Fig. 2

Cross-validation results using leave-one-out procedures showing RRMSECV values versus number of neurons for both model types: Full ANN models for (A) propranolol, (B) rosuvastatin, and (C) valsartan; and FA-ANN models for (D) propranolol, (E) rosuvastatin, and (F) valsartan. The plots demonstrate significant decreases in RRMSECV values at the optimum number of neurons for each model.